
Sanofi has scrapped its regulatory filing plans and late-stage trials for rare bone marrow cancer treatment fedratinib. The reason given …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

